In biotech, delivery is everything. Not the FedEx kind, the kind that decides whether a therapy actually lands where biology intended or gets rerouted to the liver like a missed connection. STRM.BIO...
In biotech, delivery is everything. Not the FedEx kind, the kind that decides whether a therapy actually lands where biology intended or gets rerouted to the liver like a missed connection. STRM.BIO showed up in 2019 with a quiet but dangerous idea: stop arm-wrestling biology and let it do what it already does best. Extracellular vesicles are nature's logistics network, and megakaryocytes have been running bone marrow routes long before gene therapy had a ticker symbol.
That belief just pulled in an $8M Series Seed 2, led by Recordati with Boehringer Ingelheim Venture Fund, Delos Capital returning, and Blue Bay Capital stepping in. Announced January 7, 2026, this round stacks neatly on an $8.4M ARPA-H EMBODY contract and a $2.1M SBIR grant. That is $16.4M in combined equity and non-dilutive capital secured across Q4 2025 and Q1 2026. No theatrics. Just momentum earned the hard way.
The origin story matters. Jonathan Thon, Ph.D. did not wander into this problem. Former Harvard Medical School professor, serial biotech founder, and the builder behind Platelet BioGenesis, now Stellular Bio, he launched STRM.BIO to attack the delivery bottleneck everyone else keeps politely stepping around. Viral vectors still wrestle with immunogenicity, payload limits, and liver toxicity. Megakaryocyte-derived microvesicles already know how to find the bone marrow. Biology does not need convincing.
The company is now led by Michael Luther, Ph.D., MBA, a 37+ year industry veteran with leadership time at Astellas, Merck, and GSK, with David Raiser, Ph.D. as COO keeping the engine tight. The board includes Dawn Bell, PharmD and Minnie Mildwoff, with strategic alignment from Boehringer Ingelheim Venture Fund and Recordati, whose rare disease focus fits this thesis with zero strain.
Pre-clinical does not mean pre-proof. STRM.BIO has demonstrated in vivo delivery to bone marrow stem cells in animal models without liver toxicity. Repeat dosing stays on the table. Larger genetic payloads are not a constraint. Manufacturing comes from a single bank of megakaryocytes expanded in bioreactors, frozen, shipped, thawed, and used off the shelf. This is cell biology behaving like infrastructure.
The pipeline starts with Fanconi anemia and stretches toward in vivo CAR-T and immune engineering, supported by collaborations with Ginkgo Bioworks on RNA constructs and the University of British Columbia on self-amplifying RNA. ARPA-H did not award $8.4M for a science fair project. It backed a platform designed to replace ex vivo complexity with an injection.